In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats.

BACKGROUND Ischemic acute renal failure (ARF) is a common and often fatal condition characterized by tubular epithelial cell necrosis and marked monocyte infiltration. Inflammatory mechanisms, including cell adhesion, cell infiltration, and cytokine production, are involved. These processes are thought to be directly or indirectly regulated by nuclear factor kappaB (NF-kappaB). Targeted of NF-kappaB might ameliorate ischemia/reperfusion (I/R) injury by inhibiting the production of genes that involved in ischemic ARF. The objective of the present study was to evaluate the effect of NF-kappaB decoy oligodeoxynucleotides (ODN) in experimental rat ischemic ARF. METHODS Ischemic ARF was induced by left renal artery clamping for 60 minutes, while the right kidney was being removed in female Sprague-Dawley rats. The effect of cationic liposome-protamine-NF-kappaB decoy ODN was evaluated after infusion into the kidney via the renal artery before clamping. After 24 hours of reperfusion, we then assessed morphologic and functional parameters, NF-kappaB/DNA binding activity, monocyte/macrophage (M/MPhi) infiltration, and gene expression in I/R kidney. RESULTS After 24 hours of reperfusion, compared with sham-operated animals, serum creatinine and blood urea nitrogen (BUN) levels in ischemic ARF animals were increased about 10-fold and fivefold respectively. (255.67 +/- 34.48 micromol/L vs. 25.33 +/- 2.23 micromol/L and 43.47 +/- 5.50 mmol/L vs. 8.45 +/- 0.43 mmol/L, P < 0.001), NF-kappaB/DNA binding activity was markedly elevated [median value was 1.75 vs. 0.15 relative density unit (RDU), P < 0.005]. NF-kappaB decoy ODN treatment reduced the elevation of serum creatinine level by 70% (79.17 +/- 8.64 micromol/L vs. 255.67 +/- 34.48 micromol/L, P < 0.01), BUN level by 40% (28.33 +/- 4.86 mmol/L vs. 43.47 +/- 5.50 mmol/L, P= NS), and almost abolished the NF-kappaB activation compared with levels observed in sham-operated rats (median value was 0.25 vs. 1.9 RDU, P < 0.005). Furthermore, NF-kappaB decoy ODN pretreatment prevented the occurrence of tubular necrosis and reduced the renal tubular damage scores markedly (1.85 +/- 0.06 vs. 3.63 +/- 0.06 scores, P < 0.01). In addition, M/MPhi infiltration was obviously suppressed (9.77 +/- 1.19 cells/hpf vs. 29.22 +/- 1.94 cells/hpf, P < 0.01), Moreover, results of reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry showed the up-regulation of monocyte chemoattractant protein-1 (MCP-1) and intercellular adhesion molecule-1 (ICAM-1) was greatly decreased, inducible nitric oxide synthase (iNOS) and endothelin-1 (ET-1) expression were also reduced, approaching levels observed in sham-operated animals. The data suggest that NF-kappaB decoy ODN treatment protects renal tissue from the effects of I/R injury and thus reduces the severity of ARF. CONCLUSION These experiments demonstrated that NF-kappaB plays a critical role in renal I/R injury by reducing a series of inflammatory genes. NF-kappaB decoy ODN treatment reduces the renal dysfunction and damage associated with ischemic ARF. Therefore, in vivo transfection of NF-kappaB decoy ODN provides a new therapeutic strategy for ischemic ARF.

[1]  T. Ogihara,et al.  Transfection of NFκB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts , 2003, Gene Therapy.

[2]  D. Jeyarajah,et al.  Docosahexaenoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNA abundance for both TNF-alpha and inducible nitric oxide synthase. , 2003, Journal of the American Society of Nephrology : JASN.

[3]  D. Schwartz,et al.  L-Arginine transport is augmented through up-regulation of tubular CAT-2 mRNA in ischemic acute renal failure in rats. , 2002, Kidney international.

[4]  Y. Siow,et al.  Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-kappaB. , 2002, Kidney international.

[5]  B. Krämer,et al.  A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. , 2002, Journal of the American Society of Nephrology : JASN.

[6]  A. Seguro,et al.  Mycophenolate mofetil attenuates renal ischemia/reperfusion injury. , 2002, Journal of the American Society of Nephrology : JASN.

[7]  F. Luft,et al.  Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. , 2002, Journal of the American Society of Nephrology : JASN.

[8]  M. Goligorsky,et al.  Nitric oxide in acute renal failure: NOS versus NOS. , 2002, Kidney international.

[9]  K. Matsushima,et al.  Administration of FR167653, a new anti-inflammatory compound, prevents renal ischaemia/reperfusion injury in mice. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  R. Safirstein,et al.  MONOCYTE CHEMOATTRACTANT PROTEIN-1 EXPRESSION CORRELATES WITH MONOCYTE INFILTRATION IN THE POST-ISCHEMIC KIDNEY , 2002, Renal failure.

[11]  Changchun Cao,et al.  Abnormal DNA-binding of transcription factors in minimal change nephrotic syndrome , 2001, Pediatric Nephrology.

[12]  E. Ritz,et al.  Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and βblockers , 2001 .

[13]  T. Ogihara,et al.  Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice , 2001, Gene Therapy.

[14]  J. Egido,et al.  Transcription factor-kappa B (NF-kappa B) and renal disease. , 2001, Kidney international.

[15]  T. Ogihara,et al.  Transcription factor decoy for NFκB inhibits TNF-α-induced cytokine and adhesion molecule expression in vivo , 2000, Gene Therapy.

[16]  T. Ogihara,et al.  In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. , 2000, Journal of the American Society of Nephrology : JASN.

[17]  J. Bonventre,et al.  Cell biology and molecular mechanisms of injury in ischemic acute renal failure. , 2000, Current opinion in nephrology and hypertension.

[18]  T. Rabelink,et al.  NFκB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  J. Birchall,et al.  Physical stability and in-vitro gene expression efficiency of nebulised lipid-peptide-DNA complexes. , 2000, International journal of pharmaceutics.

[20]  Simon C Watkins,et al.  Lyophilization of cationic lipid-protamine-DNA (LPD) complexes. , 2000, Journal of pharmaceutical sciences.

[21]  H. Nishimatsu,et al.  Effects of tetrahydrobiopterin on endothelial dysfunction in rats with ischemic acute renal failure. , 2000, Journal of the American Society of Nephrology : JASN.

[22]  R. Schrier,et al.  Attenuation of renal ischemia-reperfusion injury in inducible nitric oxide synthase knockout mice. , 1999, American journal of physiology. Renal physiology.

[23]  M. Corsi,et al.  RANTES and MCP-1 chemokine plasma levels in chronic renal transplant dysfunction and chronic renal failure. , 1999, Clinical Biochemistry.

[24]  Y. Wang,et al.  Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats , 1999 .

[25]  Y. Cho‐Chung,et al.  Oligonucleotides as transcription factor decoys. , 1999, Current opinion in molecular therapeutics.

[26]  B. Molitoris,et al.  The role of cell adhesion molecules in ischemic acute renal failure. , 1999, The American journal of medicine.

[27]  M. Simonson,et al.  Endothelin up-regulation and localization following renal ischemia and reperfusion. , 1999, Kidney international.

[28]  G. Burckart,et al.  Nuclear Factor Kappa B: Important Transcription Factor and Therapeutic Target , 1998, Journal of clinical pharmacology.

[29]  F. Luft,et al.  ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation. , 1998, Kidney international.

[30]  Sanchita Bhattacharya,et al.  Characterization of cationic lipid-protamine–DNA (LPD) complexes for intravenous gene delivery , 1998, Gene Therapy.

[31]  H. Rabb,et al.  Role of IL-1 in renal ischemic reperfusion injury. , 1998, Journal of the American Society of Nephrology : JASN.

[32]  S. Klahr,et al.  Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. , 1998, American journal of physiology. Renal physiology.

[33]  G. Ghosh,et al.  Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA , 1998, Nature.

[34]  Pei-ji Chen,et al.  An exceptionally well-preserved theropod dinosaur from the Yixian Formation of China , 1998, Nature.

[35]  L. Huang,et al.  In vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes , 1997, Gene Therapy.

[36]  T. Ogihara,et al.  Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer , 1997, Journal of cardiovascular pharmacology and therapeutics.

[37]  T. Ogihara,et al.  A novel strategy for gene therapy and gene regulation analysis using transcription factor decoy oligonucleotides. , 1997, Experimental nephrology.

[38]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[39]  H. Bock Pathogenesis of acute renal failure: new aspects. , 1997, Contributions to nephrology.

[40]  H. Strey,et al.  Improved DNA: liposome complexes for increased systemic delivery and gene expression , 1997, Nature Biotechnology.

[41]  H. Brady,et al.  Leukocytes, cell adhesion molecules and ischemic acute renal failure. , 1997, Kidney international.

[42]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[43]  F. Luft,et al.  Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. , 1996, Kidney international.

[44]  M. Goligorsky,et al.  In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. , 1996, The Journal of clinical investigation.

[45]  B. Rovin,et al.  Activation of nuclear factor-κB correlates with MCP-1 expression by human mesangial cells , 1995 .

[46]  F. Ledley Nonviral gene therapy: the promise of genes as pharmaceutical products. , 1995, Human gene therapy.

[47]  C. Nathan,et al.  The high‐output nitric oxide pathway: role and regulation , 1994, Journal of leukocyte biology.

[48]  P. Grace,et al.  Ischemia-reperfusion injury , 1994 .

[49]  R. Schrier,et al.  Nitric oxide: a mediator in rat tubular hypoxia/reoxygenation injury. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Colvin,et al.  Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  E. Nord Renal actions of endothelin. , 1993, Kidney international.

[52]  D. Liggitt,et al.  Systemic gene expression after intravenous DNA delivery into adult mice. , 1993, Science.

[53]  G. Nabel,et al.  Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. , 1990, Science.

[54]  K. Matsushima,et al.  Brief Definitive Report Purification and Characterization of a Novel Monocyte Chemotactic and Activating Factor Produced by a Human Myelomonocytic Cell Line , 2022 .

[55]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[56]  Hector R. Wong,et al.  Nuclear factor-κB as a therapeutic target in critical care medicine , 2003 .

[57]  L. Huang,et al.  Protamine sulfate enhances lipid-mediated gene transfer , 1997, Gene Therapy.